Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin and Piperine in Patients on Active Surveillance for MGUS, Low-risk SMM or Early Stage Prostate Cancer
NCT04731844Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Dec 2021
- Primary completion
- Sep 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of curcumin, piperine in prostate cancer (PCa), monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), sponsored by University of Rochester. Started Dec 2021; status: completed.
02
Drugs
curcuminpiperine
03
Conditions
prostate cancer (PCa)monoclonal gammopathy of undetermined significance (MGUS)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT04731844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731844.